HC Wainwright Reaffirms “Buy” Rating for LifeMD (NASDAQ:LFMD)

LifeMD (NASDAQ:LFMDGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 171.08% from the stock’s previous close.

Several other equities analysts have also commented on LFMD. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th. Zacks Research upgraded shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Weiss Ratings restated a “sell (d)” rating on shares of LifeMD in a report on Tuesday, August 4th. Lake Street Capital set a $5.00 price objective on LifeMD in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, LifeMD has an average rating of “Moderate Buy” and an average target price of $7.57.

Check Out Our Latest Report on LifeMD

LifeMD Stock Performance

Shares of LFMD traded up $0.11 during mid-day trading on Thursday, hitting $3.32. 160,481 shares of the stock were exchanged, compared to its average volume of 1,049,038. LifeMD has a 52-week low of $2.56 and a 52-week high of $7.32. The firm has a 50-day moving average of $3.58 and a two-hundred day moving average of $4.00. The company has a market cap of $160.02 million, a PE ratio of -66.49 and a beta of 2.04.

LifeMD (NASDAQ:LFMDGet Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.The company had revenue of $47.28 million during the quarter, compared to the consensus estimate of $49.16 million. On average, sell-side analysts predict that LifeMD will post -0.48 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd purchased a new position in LifeMD during the 2nd quarter worth $113,000. Integrated Wealth Concepts LLC purchased a new position in shares of LifeMD during the second quarter worth about $25,000. Penn Capital Management Company LLC acquired a new position in LifeMD in the 2nd quarter valued at about $926,000. Corient Private Wealth LP acquired a new position in shares of LifeMD in the second quarter valued at approximately $63,000. Finally, Bank of America Corp DE purchased a new position in LifeMD during the 2nd quarter worth $1,078,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

About LifeMD

(Get Free Report)

LifeMD, Inc (NASDAQ: LFMD) is a U.S.-based telehealth company that provides virtual healthcare services through its digital platform. The company connects patients with licensed healthcare professionals through online consultations, enabling access to medical care, prescriptions, ongoing treatment and care-management services without requiring an in-person visit.

LifeMD offers services across several areas, including virtual primary care, men’s and women’s health, dermatology, mental health and weight management.

Further Reading

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.